Clinical trial

Eribulin in Brain Metastases From HER2-negative Breast Cancer

NCT03637868

StatusWITHDRAWN

Study typeINTERVENTIONAL

Start date2019-02-26

PhasePHASE2

Study timeline

Study start (actual)2019-02-26Date precision: day

Registry last updated2020-05-06

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Metastatic Breast Cancerunresolved

Interventions

EribulinDRUG · verified · RxNorm: eribulin

Sponsors & collaborators

Institut Paoli-Calmetteslead sponsor

Eisai Inc.collaborator

Mapped research locations

MarseilleFrance1 MontpellierFrance1 AngersFrance1 BesançonFrance1 Saint-HerblainFrance1 Vandœuvre-lès-NancyFrance1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03637868 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.